140
Participants
Start Date
December 31, 2016
Primary Completion Date
July 31, 2021
Study Completion Date
December 31, 2021
Fenretinide
Fenretinide intravenous emulsion administered as a continuous intravenous infusion for 5 days, once every 3 weeks in relapsed/refractory PTCL patients.
RECRUITING
Bon Secours Saint Francis Cancer Center, Greenville
RECRUITING
Emory University, Atlanta
RECRUITING
Norton Healthcare, Louisville
RECRUITING
University of Louisville, Louisville
RECRUITING
University of Kansas Cancer Center, Westwood
RECRUITING
Baylor University Medical Center, Dallas
RECRUITING
University of Texas, Southwestern, Dallas
RECRUITING
Banner MD Anderson Cancer Center, Gilbert
RECRUITING
USC Norris Comprehensive Cancer Center, Los Angeles
RECRUITING
University of California, Los Angeles, Los Angeles
RECRUITING
Hackensack University Medical Center, Hackensack
Lead Sponsor
CerRx, Inc.
INDUSTRY